-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下:我们将目标股价从272美元上调至320美元,约为我们2027财年每股收益预期值的22倍,这反映出我们对JBL业务组合向高利润率的智能基础设施领域转型充满信心。我们将2027财年每股收益预期从14.00美元上调至14.70美元,并维持2026财年每股收益预期在12.25美元不变。我们信心增强的原因在于多个因素的共同作用。随着客户恢复对关键基础设施项目的资本支出,受监管行业的持续复苏势头正在增强。与此同时,互联生活和数字商务等业务板块正在经历意义深远的转型,向高利润率的自动化和机器人解决方案转型,逐步摆脱低利润率的传统制造业。这使得JBL在2027财年有望加速盈利增长,而2026财年则已初见成效。我们相信JBL正成功转型,朝着更盈利的商业模式迈进,而我们认为,这种积极的发展势头已在很大程度上反映在了当前的估值中。
Related Articles
National Australia Bank Shares Down After Resolution of Union Court Proceedings
National Australia Bank (ASX:NAB) shares were down about 1% in recent Monday trade following a Friday settlement with the Finance Sector Union of Australia to resolve court proceedings related to excessive additional working hours for employees.The settlement, reached on a without-admissions basis through mediation, includes the establishment of a health, safety, and well-being framework to mitigate the risks linked to working additional hours, and calls for greater oversight of such risks.The union and the bank said in a joint statement that they are "committed to continuing to work together to ensure fair and sustainable outcomes for all [National Australia Bank] employees."
Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant
Clinuvel Pharmaceuticals (ASX:CUV) said the US Food and Drug Administration (FDA) removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.
XRF Scientific Completes Acquisition of Combustion Gas Analysis Business
XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.